Total Payments
$43,785
2024 Payments
$302.68
Companies
28
Transactions
300
Medicare Patients
5,015
Medicare Billing
$3.4M
Payment Breakdown by Category
Other$23,245 (53.1%)
Consulting$11,448 (26.1%)
Food & Beverage$6,720 (15.3%)
Travel$2,354 (5.4%)
Education$19.20 (0.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $23,245 | 11 | 53.1% |
| Consulting Fee | $11,448 | 4 | 26.1% |
| Food and Beverage | $6,720 | 270 | 15.3% |
| Travel and Lodging | $2,354 | 12 | 5.4% |
| Education | $19.20 | 3 | 0.0% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| GENZYME CORPORATION | $33,983 | 55 | $0 (2020) |
| Biogen, Inc. | $6,024 | 87 | $0 (2024) |
| UCB, Inc. | $578.83 | 23 | $0 (2021) |
| Amgen Inc. | $431.18 | 11 | $0 (2019) |
| ACADIA Pharmaceuticals Inc | $414.15 | 28 | $0 (2020) |
| ABBVIE INC. | $405.40 | 17 | $0 (2023) |
| Genentech USA, Inc. | $239.48 | 9 | $0 (2019) |
| PFIZER INC. | $191.44 | 9 | $0 (2024) |
| Novartis Pharmaceuticals Corporation | $190.51 | 10 | $0 (2019) |
| Allergan, Inc. | $178.46 | 6 | $0 (2020) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $302.68 | 12 | Biogen, Inc. ($144.88) |
| 2023 | $436.59 | 17 | Biogen, Inc. ($200.01) |
| 2022 | $267.47 | 13 | Biogen, Inc. ($139.87) |
| 2021 | $353.63 | 22 | Biogen, Inc. ($128.32) |
| 2020 | $701.93 | 27 | Biogen, Inc. ($257.44) |
| 2019 | $11,724 | 83 | GENZYME CORPORATION ($5,840) |
| 2018 | $20,683 | 74 | GENZYME CORPORATION ($19,633) |
| 2017 | $9,316 | 52 | GENZYME CORPORATION ($8,486) |
All Payment Transactions
300 individual payment records from CMS Open Payments — Page 1 of 12
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 11/01/2024 | Biogen, Inc. | LEQEMBI (Drug) | Food and Beverage | In-kind items and services | $23.88 | General |
| Category: Neurology | ||||||
| 10/04/2024 | Biogen, Inc. | LEQEMBI (Drug) | Food and Beverage | In-kind items and services | $20.49 | General |
| Category: Neurology | ||||||
| 09/26/2024 | TG Therapeutics, Inc. | BRIUMVI (Drug) | Food and Beverage | In-kind items and services | $58.91 | General |
| Category: Immunology | ||||||
| 09/18/2024 | PFIZER INC. | NURTEC ODT (Drug), ZAVZPRET | Food and Beverage | In-kind items and services | $23.40 | General |
| Category: PAIN | ||||||
| 09/06/2024 | Biogen, Inc. | LEQEMBI (Drug) | Food and Beverage | In-kind items and services | $14.17 | General |
| Category: Neurology | ||||||
| 09/05/2024 | Biogen, Inc. | LEQEMBI (Drug) | Food and Beverage | In-kind items and services | $5.79 | General |
| Category: Neurology | ||||||
| 08/16/2024 | Biogen, Inc. | LEQEMBI (Drug) | Food and Beverage | In-kind items and services | $27.67 | General |
| Category: Neurology | ||||||
| 07/23/2024 | PFIZER INC. | NURTEC ODT (Drug), ZAVZPRET | Food and Beverage | In-kind items and services | $25.39 | General |
| Category: PAIN | ||||||
| 05/31/2024 | PFIZER INC. | NURTEC ODT (Drug), ZAVZPRET | Food and Beverage | In-kind items and services | $22.59 | General |
| Category: PAIN | ||||||
| 05/24/2024 | Biogen, Inc. | TYSABRI (Biological), VUMERITY | Food and Beverage | In-kind items and services | $27.34 | General |
| Category: Neurology | ||||||
| 02/16/2024 | Biogen, Inc. | TYSABRI (Biological), VUMERITY | Food and Beverage | In-kind items and services | $25.54 | General |
| Category: Neurology | ||||||
| 02/09/2024 | PFIZER INC. | NURTEC ODT (Drug), ZAVZPRET | Food and Beverage | In-kind items and services | $27.51 | General |
| Category: PAIN | ||||||
| 11/14/2023 | ABBVIE INC. | UBRELVY (Drug), QULIPTA | Food and Beverage | In-kind items and services | $29.53 | General |
| Category: NEUROSCIENCE | ||||||
| 11/03/2023 | Biogen, Inc. | TYSABRI (Biological), VUMERITY | Food and Beverage | In-kind items and services | $26.78 | General |
| Category: Neurology | ||||||
| 10/06/2023 | ABBVIE INC. | QULIPTA (Drug) | Food and Beverage | In-kind items and services | $34.90 | General |
| Category: NEUROSCIENCE | ||||||
| 10/06/2023 | Biogen, Inc. | TYSABRI (Biological), VUMERITY | Food and Beverage | In-kind items and services | $27.88 | General |
| Category: Neurology | ||||||
| 10/05/2023 | Biogen, Inc. | — | Food and Beverage | In-kind items and services | $5.00 | General |
| 09/29/2023 | ABBVIE INC. | BOTOX (Biological) | Food and Beverage | In-kind items and services | $31.48 | General |
| Category: NEUROSCIENCE | ||||||
| 08/25/2023 | Eisai Inc. | Leqembi (Drug) | Food and Beverage | Cash or cash equivalent | $22.04 | General |
| Category: Neurology | ||||||
| 08/17/2023 | PFIZER INC. | PAXLOVID (Drug), NURTEC ODT, ZAVZPRET | Food and Beverage | In-kind items and services | $27.00 | General |
| Category: INFECTIOUS DISEASES | ||||||
| 08/03/2023 | Biogen, Inc. | — | Food and Beverage | In-kind items and services | $24.94 | General |
| 07/21/2023 | ABBVIE INC. | BOTOX (Biological) | Food and Beverage | In-kind items and services | $33.91 | General |
| Category: BOTOX THERAPEUTIC | ||||||
| 06/20/2023 | Biogen, Inc. | — | Food and Beverage | In-kind items and services | $44.46 | General |
| 06/09/2023 | ABBVIE INC. | BOTOX (Biological) | Food and Beverage | In-kind items and services | $33.91 | General |
| Category: NEUROSCIENCE | ||||||
| 06/09/2023 | PFIZER INC. | PAXLOVID (Drug), NURTEC ODT, ZAVZPRET | Food and Beverage | In-kind items and services | $23.81 | General |
| Category: INFECTIOUS DISEASES | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 7 | 1,126 | 9,048 | $1.1M | $716,842 |
| 2022 | 7 | 1,087 | 9,058 | $1.1M | $652,979 |
| 2021 | 7 | 1,529 | 14,636 | $1.8M | $1.1M |
| 2020 | 7 | 1,273 | 12,627 | $1.5M | $929,745 |
Total Patients
5,015
Total Services
45,369
Medicare Billing
$3.4M
Procedure Codes
28
All Medicare Procedures & Services
28 procedure records from CMS Medicare Utilization — Page 1 of 2
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99232 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | Facility | 2023 | 385 | 6,570 | $657,000 | $435,393 | 66.3% |
| 99233 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | Facility | 2023 | 113 | 1,160 | $150,770 | $115,442 | 76.6% |
| 99291 | Critical care, first 30-74 minutes | Facility | 2023 | 26 | 570 | $162,450 | $100,405 | 61.8% |
| 99222 | Initial hospital care with straightforward or low-level medical decision making, if using time, at least 55 minutes | Facility | 2023 | 233 | 248 | $74,400 | $26,881 | 36.1% |
| 95819 | Measurement of brain wave activity (eeg), awake and asleep | Facility | 2023 | 239 | 288 | $43,200 | $13,643 | 31.6% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 47 | 129 | $19,350 | $13,020 | 67.3% |
| 99223 | Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes | Facility | 2023 | 83 | 83 | $29,050 | $12,060 | 41.5% |
| 99232 | Follow-up hospital inpatient care per day, typically 25 minutes | Facility | 2022 | 235 | 5,175 | $517,500 | $311,503 | 60.2% |
| 99233 | Follow-up hospital inpatient care per day, typically 35 minutes | Facility | 2022 | 228 | 3,101 | $403,130 | $268,617 | 66.6% |
| 99222 | Initial hospital inpatient care per day, typically 50 minutes | Facility | 2022 | 183 | 188 | $56,400 | $21,414 | 38.0% |
| 99223 | Initial hospital inpatient care per day, typically 70 minutes | Facility | 2022 | 119 | 121 | $42,350 | $20,238 | 47.8% |
| 95819 | Measurement of brain wave activity (eeg), awake and asleep | Facility | 2022 | 248 | 334 | $50,100 | $16,429 | 32.8% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 60 | 125 | $18,750 | $12,730 | 67.9% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2022 | 14 | 14 | $4,200 | $2,049 | 48.8% |
| 99232 | Subsequent hospital inpatient care, typically 25 minutes per day | Facility | 2021 | 347 | 8,439 | $843,900 | $518,745 | 61.5% |
| 99233 | Subsequent hospital inpatient care, typically 35 minutes per day | Facility | 2021 | 261 | 5,051 | $656,630 | $446,306 | 68.0% |
| 99223 | Initial hospital inpatient care, typically 70 minutes per day | Facility | 2021 | 233 | 245 | $85,750 | $41,973 | 48.9% |
| 99222 | Initial hospital inpatient care, typically 50 minutes per day | Facility | 2021 | 296 | 327 | $98,100 | $37,888 | 38.6% |
| 95819 | Measurement and recording of brain wave (eeg) activity, awake and asleep | Facility | 2021 | 285 | 385 | $57,750 | $19,389 | 33.6% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Office | 2021 | 77 | 159 | $22,300 | $16,184 | 72.6% |
| 99204 | New patient outpatient visit, total time 45-59 minutes | Office | 2021 | 30 | 30 | $9,000 | $4,291 | 47.7% |
| 99232 | Subsequent hospital inpatient care, typically 25 minutes per day | Facility | 2020 | 304 | 8,098 | $809,800 | $507,367 | 62.7% |
| 99233 | Subsequent hospital inpatient care, typically 35 minutes per day | Facility | 2020 | 243 | 3,574 | $464,620 | $323,783 | 69.7% |
| 99223 | Initial hospital inpatient care, typically 70 minutes per day | Facility | 2020 | 202 | 208 | $72,800 | $36,517 | 50.2% |
| 99222 | Initial hospital inpatient care, typically 50 minutes per day | Facility | 2020 | 208 | 222 | $66,600 | $26,412 | 39.7% |
About Dr. Robert Giombetti, M.D
Dr. Robert Giombetti, M.D is a Neurology healthcare provider based in Marina Del Rey, California. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 11/17/2006. The National Provider Identifier (NPI) number assigned to this provider is 1659445211.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Robert Giombetti, M.D has received a total of $43,785 in payments from pharmaceutical and medical device companies, with $302.68 received in 2024. These payments were reported across 300 transactions from 28 companies. The most common payment nature is "Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program" ($23,245).
As a Medicare-enrolled provider, Giombetti has provided services to 5,015 Medicare beneficiaries, totaling 45,369 services with total Medicare billing of $3.4M. Data is available for 4 years (2020–2023), covering 28 distinct procedure/service records.
Ad
Practice Information
- Specialty Neurology
- Location Marina Del Rey, CA
- Active Since 11/17/2006
- Last Updated 03/25/2010
- Taxonomy Code 2084N0400X
- Entity Type Individual
- Practice Solo Practitioner
- NPI Number 1659445211
Products in Payments
- AUBAGIO (Drug) $33,940
- Vumerity (Drug) $4,009
- TYSABRI (Biological) $656.05
- Briviact (Drug) $500.30
- NUPLAZID (Drug) $414.15
- UBRELVY (Drug) $318.80
- Aimovig (Biological) $284.30
- VUMERITY (Drug) $251.50
- RYTARY (Drug) $182.10
- NURTEC ODT (Drug) $176.28
- OCREVUS (Biological) $154.75
- TECFIDERA (Drug) $149.97
- AJOVY (Drug) $149.95
- QULIPTA (Drug) $121.08
- BOTOX (Biological) $99.30
- LEQEMBI (Drug) $92.00
- Non-Covered Product (Drug) $84.73
- Vimpat (Drug) $78.53
- Fycompa (Drug) $70.84
- GILENYA (Drug) $67.29
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.